EGFR and glioblastoma: According to this retrospective clinical data set, which includes MGMT-, EGFR- and EGFRvIII-status, EGFRvIII positivity but not EGFR amplification is a positive predictor of response to standard of care first line treatment in MGMT-M GBM patients.